Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia

Severe Chronic Neutropenia Clinical Trial

Official title:
Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Severe Chronic Neutropenia

Status Terminated

Clinical Trial Summary

This is a multicenter Phase 2 randomized parallel-group study to determine the effect of Telintra treatment on severe chronic neutropenia. Patients will be randomized to Telintra or enter an observation period with an option to crossover to Telintra treatment in a 1:1 allocation.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00909584
Study type	Interventional
Source	Telik
Contact
Status	Terminated
Phase	Phase 2
Start date	April 2009
Completion date	May 2013

View Details

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT01859637` - Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia	Phase 4
	Enrolling by invitation	`NCT01852370` - Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases	Phase 1/Phase 2